Zaiding Pharmaceutical released its financial report for the second quarter of 2026. The company's total revenue for the period was US$106.3 million, compared to US$110 million in the same period last year; product revenue was US$105.8 million, up 11% month-on-month; and net loss was US$50.8 million, or US$40.7 million for the same period last year. By the end of June, the company's cash and short-term investments totaled US$717.5 million. The company expects 3 registered studies to be carried out before the end of the year. DLL3 ADC Zoci first-line small cell lung cancer data will be announced at the ESMO conference in October, and plans to launch a registered phase 3 study in the second half of the year; the key phase 3 of second-line and above small cell lung cancer is expected to complete enrollment in the first half of 2027, which is expected to support the company to submit its first US listing application.

Zaiding Pharmaceutical released its financial report for the second quarter of 2026. The company's total revenue for the period was US$106.3 million, compared to US$110 million in the same period last year; product revenue was US$105.8 million, up 11% month-on-month; and net loss was US$50.8 million, or US$40.7 million for the same period last year. By the end of June, the company's cash and short-term investments totaled US$717.5 million. The company expects 3 registered studies to be carried out before the end of the year. DLL3 ADC Zoci first-line small cell lung cancer data will be announced at the ESMO conference in October, and plans to launch a registered phase 3 study in the second half of the year; the key phase 3 of second-line and above small cell lung cancer is expected to complete enrollment in the first half of 2027, which is expected to support the company to submit its first US listing application.